Desensitization of 5-HT 1A receptors could be involved in the long-term therapeutic effect of anxiolytic and antidepressant drugs. Pretreatment of rats with the 5-HT 2A/2C agonist DOI induces an attenuation of hypothalamic 5-HT 1A receptor-G zprotein signaling, measured as the ACTH and oxytocin responses to an injection of the 5-HT 1A agonist 8-OH-DPAT. We characterized this functional heterologous desensitization of 5-HT 1A receptors in rats and examined some of the mechanisms that are involved. A time course experiment revealed that DOI produces a delayed and reversible reduction of the ACTH and oxytocin responses to an 8-OH-DPAT challenge. The maximal desensitization occurred at 2 hr, and it disappeared 24 hr after DOI injection. The desensitization was dose-dependent, and it shifted the oxytocin and ACTH dose-response curves of 8-OH-DPAT to the right (increased ED 50 ) with no change in their maximal responses (E max ). The 5-HT 2A receptor antagonist MDL 100,907 prevented the DOI-induced desensitization, indicating that 5-HT 2A receptors mediate the effect of DOI. Analysis of the components of the 5-HT 1A receptor-G z -protein signaling system showed that DOI did not alter the level of membraneassociated G z -proteins in the hypothalamus. Additionally, DOI did not alter the binding of 
Among the seven families of serotonin receptors, 5-HT 1A and 5-HT 2A receptors have an important role in mood disorders (Stockmeier et al., 1997; Staley et al., 1998; Olivier et al., 1999; Sargent et al., 2000) . Selective serotonin reuptake inhibitors (SSRIs) produce a desensitization of 5-HT 1A receptors (Li et al., 1996; Berlin et al., 1998; Bosker et al., 2001 ) and alter the functioning of 5-HT 2A receptors (Tilakaratne et al., 1995; Bonson et al., 1996; . Desensitization of 5-HT 1A receptors could contribute to the therapeutic effects of SSRIs. Because chronic treatment with SSRIs results in long-term elevation in the levels of 5-HT in the synapse, SSRIs could produce a heterologous desensitization of 5-HT 1A receptors by the activation of other 5-HT receptors.
5-HT 1A receptors and 5-HT 2 receptors interact via their signaling proteins (Katada et al., 1985; Berg et al., 1998; Tournois et al., 1998; Evans et al., 2001) . In Chinese hamster ovary (CHO) cells stably expressing the human 5-HT 1A receptors and 5-HT 2C receptors, the activation of 5-HT 2C receptors induces a heterologous desensitization of 5-HT 1A receptors via protein kinase C and a cyclooxygenase-dependent metabolite of arachidonic acid (Evans et al., 2001 ). 5-HT 2A receptors are coupled also via G q /11 proteins to phospholipase C and phospholipase A 2 signaling pathways (Garcia and Kim, 1997; Grotewiel and Sanders-Bush, 1999 ). Thus 5-HT 2A receptors could cross-talk to 5-HT 1A receptors to produce a heterologous desensitization of 5-HT 1A receptors.
Functional interactions between 5-HT 1A receptors and 5-HT 2A /2C receptors have been demonstrated in behavioral studies. These studies either examined the effect of 5-HT 1A receptor activation on 5-HT 2A /2C receptor-mediated behaviors (Darmani et al., 1990; Krebs-Thomson and Geyer, 1998) or determined the impact of 5-HT 2A /2C receptor desensitization on the behavioral and temperature responses to 5-HT 1A receptor activation (Hensler and Truett, 1998) . To our knowledge, only one group has examined the impact of 5-HT 2A /2C receptor activation on the reproductive behavioral response to 8-OH-DPAT (Maswood and Uphouse, 1997 (Appel et al., 1990; Li et al., 1997) , where oxytocin and corticotropin-releasing factor (CRF) cells are located (Sawchenko and Swanson, 1985) . Evidence indicates that 8-OH-DPAT-induced release of oxytocin and adrenocorticotropic hormone (ACTH) is mediated by 5-HT 1A receptor-G z -protein signaling in the hypothalamic paraventricular nucleus (Serres et al., 2000) . Activation of hypothalamic 5-HT 2A receptors also mediates oxytocin and ACTH release (Bagdy 1996; Van de Kar et al., 2001) . Thus the 8-OH-DPAT-induced increase in the plasma levels of ACTH and oxytocin is a useful index of the sensitivity of hypothalamic 5-HT 1A receptors and can be used to examine the interaction between 5-HT 2A and 5-HT 1A receptors in the hypothalamus.
The present study is the first in vivo characterization of a functional heterologous desensitization of 5-HT 1A receptors after 5-HT 2A receptor activation with DOI. In addition, the hypothalamic levels of membrane-associated G z -protein and the coupling of hypothalamic 5-HT 1A receptors to G-proteins were examined as possible underlying mechanisms for this heterologous desensitization.
MATERIALS AND METHODS Animals
Male Sprague Dawley rats (225-275 gm) were purchased from Harlan Sprague Dawley (Indianapolis, I N). The rats were housed two per cage in a temperature-, humidity-, and light-controlled room (12 hr light /dark cycle, lights on from 7:00 A.M. to 7:00 P.M.). Food and water were available ad libitum. All procedures were conducted in accordance with National Institutes of Health Guide for the Care and Use of Laborator y Animals as approved by L oyola University Institutional Animal C are and Use Committee.
Drugs
Ϯ8-Hydroxy-2-(di-n-propylamino) tetralin hydrobromide ([ 3 H]8-OH-DPAT) and (Ϯ)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane HC l (DOI) were purchased from Research Biochemicals (Natick, M A). (Ϯ)-␣-(2,3-Dimethox y phenyl)-1-(2-fluorophenylethyl-4-piperidinemethanol (MDL 100,907) was donated generously by Hoechst Marion Roussel Research Institute (C incinnati, OH). 8-OH-DPAT was dissolved in 0.9% saline at four concentrations (0.03, 0.05, 0.1, and 0.5 mg /ml). DOI was dissolved in 0.9% saline at three concentrations (0.5, 2.5, and 5 mg /ml). MDL 100,907 was dissolved in a minimal volume of 0.01N HC l and diluted with saline to the final concentration of 0.01 mg /ml. All solutions were made fresh before injections and injected at a volume of 1 ml / kg.
Experimental protocols
After their arrival, the rats were housed two per cage for at least 1 week, followed by 4 d of handling. On the day of the experiments the rats were assigned randomly to different experimental groups (n ϭ 8 per group) to receive drug treatments. C age mates were assigned to the same treatment group. After receiving different drug treatments, the rats were decapitated. The trunk blood was collected in centrif uge tubes containing a 0.5 ml solution of 0.3 M EDTA, pH 7.4. After centrif ugation the plasma was stored at Ϫ70°C for radioimmunoassays of plasma hormone concentrations. The hypothalamus was dissected, immediately frozen in liquid nitrogen, and later stored at Ϫ70°C for immunoblot analysis and receptor binding assays.
T ime course of the effect of DOI on hormone responses to an 8-OH-DPAT challenge. The 5-HT 2A /2C receptor agonist DOI (2.5 mg / kg, i.p.) or saline was administered to rats. At different time points after DOI injection (1, 2, 4, 24 hr) the rats were challenged with the 5-HT 1A agonist 8-OH-DPAT (0.05 mg / kg, s.c.) or saline. Then 15 min after the 8-OH-DPAT injection the rats were decapitated.
Effect of pretreatment with increasing doses of DOI on hormone responses to an 8-OH-DPAT challenge. Rats were injected with increasing doses of DOI (0.5, 2.5 and 5 mg / kg, i.p.) or saline. At 2 hr later the rats were challenged with 8-OH-DPAT (0.05 mg / kg, s.c.) or saline. Then 15 min after the 8-OH-DPAT challenge the rats were decapitated.
Dose-response to an 8-OH-DPAT challenge in rats pretreated with DOI. Rats were injected with DOI (2.5 mg / kg, i.p.) or saline. At 2 hr later the rats were challenged with saline or increasing doses of 8-OH-DPAT (0.03, 0.05, 0.1, 0.5 mg / kg, s.c.). Then 15 min after the 8-OH-DPAT challenge the rats were decapitated.
Pretreatment with the 5-HT 2A antagonist MDL 100,907. Rats first received an injection of vehicle or the 5-HT 2A antagonist MDL 100,907 (0.01 mg / kg, s.c.). At 15 min after this injection the rats received an injection of DOI (2.5 mg / kg, i.p.) or saline. Then 2 hr after the DOI injection the rats were challenged with 8-OH-DPAT (0.05 mg / kg, s.c.) or saline. The rats were decapitated 15 min after the 8-OH-DPAT challenge.
Radioimmunoassay
Plasma oxytocin and AC TH were determined by radioimmunoassays as described previously in detail (Li et al., 1993 (Li et al., , 1997 .
Immunoblot analysis of G z -proteins
T issue preparation. All procedures were conducted at 4°C. Briefly, the hypothalamic tissues were homogenized in 0.4 ml of 50 mM Tris buffer, pH 7.4, containing 150 mM NaCl, 10% sucrose, and 0.5 mM phenylmethanesulfonyl fluoride (PMSF) and additional protease inhibitors purchased as a cocktail [containing 4-(2-aminoethyl)benzenesulfonyl fluoride, pepstatin A, trans-epoxysuccinyl-L-leucyl-amido(4-guanidino)butane, bestatin, leupeptin, and aprotinin] from Sigma (1.5 l/30 mg tissue; St. Louis, MO). After centrifugation at 20,000 ϫ g for 60 min the pellets were collected and resuspended by sonication in a 20 mM Tris buffer, pH 8 [containing (in mM) 1 EDTA, 100 NaCl, 1 dithiothreitol, and 1% sodium cholate] plus the protease inhibitory cocktail (1.5 l cocktail/30 mg tissue) in a ratio of 3 l buffer/mg tissue. The resuspended pellets were incubated while shaking for 1 hr and then centrif uged at 100,000 ϫ g for 60 min. The supernatant was collected for the immunoblot analysis of membrane-bound G z -protein levels. The protein concentration was measured with a bicinchoninic acid (BCA) protein assay kit (Pierce, Rockford, IL).
Quantification of G z -protein.
Immunoblot analysis of membraneassociated G z -proteins has been described previously in detail Serres et al., 2000) . Briefly, the solubilized proteins (2 g / lane) were resolved by SDS-PAGE and then transferred electrophoretically to nitrocellulose membranes. After incubation with a blocking buffer (PBS containing 0.2% casein and 0.1% T ween 20), the nitrocellulose membranes were probed overnight at 4°C with polyclonal antisera for G z (I-20, 1:6000 dilution; Santa Cruz Biotechnology, Santa Cruz, CA). Then the membranes were incubated with a secondary antibody (goat antirabbit serum, 1:25,000 dilution for 1 hr; C appell, Organon Teknika, Durham, NC), followed by an incubation with rabbit peroxidase antiperoxidase (1:5000 dilution for 1 hr; C appell, Organon Teknika). Finally, the membranes were incubated with the ECL chemiluminescence substrate solution (Amersham, Arlington Heights, IL) and then exposed to Kodak x-ray film. Films were analyzed densitometrically with the Scion Image program (Frederick, MD). The data for each sample were the means of three replications and were calculated as integrated optical densities (IOD)/g protein. The percentile changes of the mean IOD/g protein values of each sample were calculated with respect to the average of IOD/g protein values of saline-treated samples.
[ 3 H]8-OH-DPAT binding
All procedures were performed on ice. The hypothalamic tissues were homogenized quickly in 2 ml Tris buffer (50 mM), pH 7.7, using a Polytron, and were centrif uged at 35,000 ϫ g for 10 min. The pellets were resuspended with 2 ml of 50 mM Tris buffer, and the procedure was repeated four times. Then the samples were diluted to a final concentration of 20 mg of tissue per milliliter for the receptor binding assay. 
Statistical analyses
The data are presented as group means (n ϭ 8) and the SEM. E xcept for immunoblot data, all other data were analyzed by two-way or three-way ANOVA. Group means were compared by a Newman -Keuls multiple range test (Steel and Torrie, 1960) . The immunoblot data were analyzed by a Student's t test. A computer program (GBSTAT, Silver Spring, MD) was used for all of the statistical analyses.
RESULTS

Time course of the effect of DOI on hormone responses to a challenge with a 5-HT 1A agonist
The 5-HT 2A /2C receptor agonist DOI (2.5 mg/kg, i.p.) was injected at different time points (1, 2, 4, 24 hr) before 8-OH-DPAT challenge. DOI alone did not alter plasma oxytocin and ACTH levels significantly at these time points. 8-OH-DPAT significantly increased the plasma levels of oxytocin and ACTH by 731 and 930%, respectively. The time course effects of DOI on oxytocin (Fig. 1 A) and ACTH (Fig. 1 B) showed a delayed onset and reversible inhibition, by DOI, of the hormone responses to the subsequent challenge with 8-OH-DPAT. For oxytocin the threeway ANOVA indicated no significant main effects of time (F (3, 107) ϭ 0.04; p Ͼ 0.1) but a significant main effect of DOI (F (1,107) ϭ 9.96; p Ͻ 0.01) and 8-OH-DPAT (F (1,107) ϭ 270.51; p Ͻ 0.01). The interaction between time and DOI was not significant. However, there was a significant interaction between DOI and 8-OH-DPAT (F (1,107) ϭ 10.55; p Ͻ 0.01). For ACTH the threeway ANOVA indicated that there was a significant main effect of 8-OH-DPAT (F (1,106) ϭ 319.56; p Ͻ 0.01). The main effect of time (F (3, 106) ϭ 2.45; p Ͼ 0.05) and the main effect of DOI (F (1,106) ϭ 3.23; p Ͼ 0.05) were not significant. However, both the interactions between time and DOI (F (3, 106) ϭ 4.75; p Ͻ 0.05) and between DOI and 8-OH-DPAT (F (1,106) ϭ 10.48; p Ͻ 0.05) were significant. The Newman-Keuls test indicated that DOI significantly decreased both plasma oxytocin and ACTH responses to the 8-OH-DPAT challenge at 2 and 4 hr, with a maximal effect at 2 hr post-DOI administration (47% reduction for oxytocin; 51% reduction for ACTH) (Fig. 1) . At 1 hr after treatment with DOI there was no inhibition of the effect of 8-OH-DPAT on either ACTH or oxytocin levels (Fig. 1) . These observations indicate that activation of 5-HT 2A /2C receptors produces a transient and delayed onset attenuation of 5-HT 1A receptor-mediated secretion of oxytocin and ACTH.
Effect of pretreatment with increasing doses of DOI on hormone responses to 8-OH-DPAT
DOI was administered at three doses: 0.5, 2.5, and 5 mg/kg intraperitoneally, respectively. Basal plasma levels of oxytocin and ACTH in saline-challenged rats were not altered significantly by DOI at these doses. However, DOI inhibited the oxytocin (Fig.  2 A) response to 8-OH-DPAT challenge in a dose-dependent manner. For plasma oxytocin the two-way ANOVA indicated a significant main effect of both DOI (F (3, 55) ϭ 2.92; p Ͻ 0.05) and 8-OH-DPAT (F (1,55) ϭ 71.08; p Ͻ 0.01). There was a significant interaction between DOI and 8-OH-DPAT (F (3, 55) ϭ 3.08; p Ͻ 0.05). The Newman-Keuls test indicated that DOI significantly reduced the effect of 8-OH-DPAT on plasma oxytocin levels at the doses of 2.5 mg/kg (by 40%; p Ͻ 0.05) and 5 mg/kg (by 58%; p Ͻ 0.01). For plasma ACTH in this experiment the two way ANOVA indicated a significant main effect of 8-OH-DPAT (F (1,54) ϭ 119.82; p Ͻ 0.01), but no significant main effect of DOI (F (3, 54) ϭ 0.25; p Ͼ 0.1) and no significant interaction between DOI and 8-OH-DPAT (F (3, 54) ϭ 1.47; p Ͼ 0.1). However, baseline levels of ACTH were elevated from 43.1 Ϯ 3.4 to 99.6 Ϯ 12.8. Subtracting the baseline levels from 8-OH-DPAT-stimulated ACTH release would indicate that the additive effects of DOI on basal ACTH levels could have masked its desensitizing effects (saline/DPAT group, 382.2; DOI 0.5/DPAT group, 326.6; DOI 2.5/DPAT group, 271.2; DOI 5/DPAT group, 228.4 pg/ml). Hence the highest dose of DOI produced a Ͼ40% inhibition of the ACTH response to 8-OH-DPAT.
Dose-response effect of 8-OH-DPAT in rats pretreated with DOI
Increasing doses of 8-OH-DPAT (0.03, 0.05, 0.1, 0.5 mg/kg, s.c.) or saline were administered 2 hr after DOI (2.5 mg/kg, i.p.) or saline treatments. In saline-pretreated rats, 8-OH-DPAT significantly increased plasma oxytocin and ACTH levels in a dosedependent manner. At the doses of 0.05 and 0.1 mg/kg, 8-OH-DPAT increased plasma oxytocin to 53 and 80% of maximal response, respectively. However, ACTH is a more amplified hormone. At the dose of 0.05 mg/kg, 8-OH-DPAT produced a maximal increase in plasma ACTH levels. DOI treatment shifted both oxytocin (Fig. 3A) and ACTH (Fig. 3B) dose-response curves to the right, with no change in E max . For plasma oxytocin the two-way ANOVA showed a significant main effect of DOI (F (1,67) ϭ 7.26; p Ͻ 0.01) and a significant main effect of 8-OH-DPAT (F (4,67) ϭ 120.00; p Ͻ 0.01). The interaction between DOI and 8-OH-DPAT was also significant (F (4,67) ϭ 3.72; p Ͻ 0.01). The Newman-Keuls test indicated that, in saline-pretreated rats, 8-OH-DPAT at the dose of 0.03 mg/kg produced no significant effect. At the doses of 0.05 and 0.1 mg/kg, 8-OH-DPAT significantly elevated plasma oxytocin levels. Basal plasma oxytocin level in saline-challenged rats was not altered by DOI. However, DOI significantly lowered the oxytocin responses to 8-OH-DPAT at the challenge doses of 0.05 mg/kg ( p Ͻ 0.05) and 0.1 mg/kg ( p Ͻ 0.01), but not at the highest dose of 0.5 mg/kg (Fig. 3A) . For plasma ACTH the two-way ANOVA indicated a significant main effect of DOI (F (1,60) ϭ 4.67; p Ͻ 0.05) and a significant main effect of 8-OH-DPAT (F (4,60) ϭ 47.7; p Ͻ 0.01). There was a significant interaction between DOI and 8-OH-DPAT (F (4,60) ϭ 6.45; p Ͻ 0.01). The Newman-Keuls test indicated that 0.03 mg/kg 8-OH-DPAT produced no significant effect on plasma ACTH. However, a dose of 0.05 mg/kg 8-OH-DPAT already increased plasma ACTH to its maximal level. Basal plasma ACTH level in saline-challenged rats was not altered by DOI. However, DOI significantly lowered the ACTH response to 8-OH-DPAT at the challenge doses of 0.05 mg/kg ( p Ͻ 0.01) and 0.1 mg/kg ( p Ͻ 0.05), respectively, but not at the dose of 0.5 mg/kg (Fig. 3B) . 
Pretreatment with the 5-HT 2A antagonist MDL 100,907 prevents DOI-induced reduction of hormone responses to 8-OH-DPAT
The basal plasma levels of oxytocin and ACTH were not altered by MDL 100,907 or by DOI. The 8-OH-DPAT challenge significantly elevated both plasma levels of oxytocin (Fig. 4 A) and ACTH (Fig. 4 B) . The three-way ANOVA indicated that there was no significant main effect of MDL 100,907 for oxytocin (F (1,55) ϭ 2.74; p Ͼ 0.1) and ACTH (F (1,55) ϭ 1.08; p Ͼ 0.1). For oxytocin there were significant interactions between MDL 100,907 and DOI (F (1,55) ϭ 7.17; p Ͻ 0.01) as well as among MDL 100,907, DOI, and 8-OH-DPAT (F (1,55) ϭ 6.41; p Ͻ 0.05). For ACTH the main effect of 8-OH-DPAT was significant (F (1,55) ϭ 109.11; p Ͻ 0.01), but neither the interaction between MDL 100,907 and DOI nor the interaction among MDL 100,907, DOI, and 8-OH-DPAT was significant. However, the Newman-Keuls test indicated that MDL 100,907 blocked the ability of DOI to inhibit the effect of 8-OH-DPAT on plasma levels of oxytocin (Fig. 4 A) and ACTH (Fig. 4 B) . Thus the effect of DOI on both hormone responses to 8-OH-DPAT challenge is mediated predominantly by the activation of 5-HT 2A receptors.
DOI does not change the level of membraneassociated G z -proteins in the hypothalamus
The concentration of membrane-associated G z -proteins in the hypothalamus of DOI-and saline-treated rats was measured by immunoblot analysis. The specificity of the antibody for G zprotein has been verified in a previous study ). An example of an immunoblot of membrane-bound G z -proteins is shown in Figure 5A . The result of the densitometric analysis is presented in Figure 5B . A Student's t test indicates that hypothalamic levels of membrane-associated G z -proteins were not reduced significantly by 2.5 mg/kg DOI intraperitoneally, a dose that significantly reduces hormone responses to an 8-OH-DPAT challenge. (Fig. 6 A) .
DOI does not change the GTP␥S-induced inhibition of
We used 0.02 M (IC 50 ) and 1 M (E max ) concentrations of GTP␥S to examine the degree of inhibition of [ 3 H]8-OH-DPAT (0.8 nM) binding in the hypothalamic homogenates from salineand DOI-treated rats. The two-way ANOVA indicated that there was a significant main effect of GTP␥S (F (42,2) ϭ 374.54; p Ͻ 0.01), but no significant main effect of DOI (F (42,1) ϭ 2.45; p Ͼ 0.1). The interaction between GTP␥S and DOI was not signifi- (Fig. 6 B) . These data suggest that DOI treatment does not reduce the coupling of 5-HT 1A receptors to G-proteins in the hypothalamus.
DISCUSSION
The present study provides the first in vivo demonstration of a functional heterologous desensitization of hypothalamic 5-HT 1A receptors after activation of 5-HT 2A receptors. The main findings are that (1) activation of 5-HT 2A receptors with DOI produces a delayed and transient reduction of 5-HT 1A receptor-mediated secretion of oxytocin and ACTH, with an increase in ED 50 and no change in E max , and that (2) DOI treatment does not change the level of membrane-associated G z -protein or the coupling of 5-HT 1A receptors to G-proteins in the hypothalamus.
8-OH-DPAT, the prototypical 5-HT 1A receptor agonist, has a high affinity for 5-HT 1A receptors and from 10-to 100-fold lower affinity for other 5-HT receptor subtypes (Hoyer et al., 1994) . The effect of 8-OH-DPAT on the secretion of ACTH and oxytocin is inhibited by the 5-HT 1A antagonists WAY100635, NAN-190, and pindolol (Bagdy and Kalogeras, 1993; Critchley et al., 1994; Meller and Bohmaker, 1994; Vicentic et al., 1998) . Thus the changes in plasma levels of ACTH and oxytocin after an 8-OH-DPAT challenge reflect the functional state of the 5-HT 1A receptor system. DOI is a 5-HT 2A /2C agonist with a similar affinity for 5-HT 2A and 5-HT 2C receptors (Hoyer, 1988) . Therefore, we used MDL 100,907 to determine whether 5-HT 2A or 5-HT 2C receptors mediate the DOI-induced desensitization of 5-HT 1A receptors. MDL 100,907 is a selective antagonist with Ͼ100-fold higher affinity for 5-HT 2A than for 5-HT 2C receptors Kehne et al., 1996) . The dose of MDL 100,907 (0.01 mg/kg) used in the present study was selected to avoid occupancy of 5-HT 2C receptors (Dekeyne et al., 1999; Smith et al., 1999) . Thus the ability of MDL 100,907 to block the effect of DOI indicates that 5-HT 2A receptors mediate the DOI-induced desensitization of hypothalamic 5-HT 1A receptors.
Although evidence exists for receptor reserve in 5-HT 1A receptor-induced release of ACTH (Meller and Bohmaker, 1994) , oxytocin is a more direct indicator of the functioning of the hypothalamic 5-HT 1A receptors after 8-OH-DPAT challenge (Serres et al., 2000) . A dose of 0.05 mg/kg 8-OH-DPAT produces a maximal release of ACTH but only 50% of the maximal response of oxytocin (Fig. 3) . This difference in amplification may explain our observation that DOI attenuates the oxytocin response to 8-OH-DPAT in a dose-dependent manner (Fig. 2 A) , whereas the inhibition of the ACTH response to 8-OH-DPAT is less dramatic (Fig. 2 B) .
DOI increases the secretion of oxytocin and AC TH by activating 5-HT 2A receptors in the hypothalamic paraventricular nucleus (Van de Kar et al., 2001 ). It could be argued that a reduction of hormone responses to a subsequent 8-OH-DPAT challenge is attributable to a hormone-depleting effect of DOI. However, the time course experiment indicates that, 1 hr after treatment with DOI, there is no desensitization of the oxytocin or AC TH responses to 8-OH-DPAT even if one would subtract from the AC TH response the effect of DOI on baseline AC TH levels (Fig. 1) . If the pretreatment with DOI would have depleted oxytocin, CRF, or AC TH stores, there should have been a reduced response to 8-OH-DPAT at 1 hr after DOI treatment. In addition, DOI pretreatment did not reduce the maximal hormone responses to 8-OH-DPAT challenge (Fig.  3) . This indicates that DOI pretreatment has not depleted hormone stores. Thus DOI-induced attenuation of hormone responses to the 8-OH-DPAT challenge is more likely to be attributable to a heterologous desensitization of hypothalamic 5-HT 1A receptors.
The hypothalamic paraventricular nucleus is crucial for the serotonergic stimulation of AC TH and oxytocin release (Liposits et al., 1987; Saphier, 1991; Kawano et al., 1992 ; Bagdy 
